The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.

abstract：:In 1993, interferon (IFN)-beta(1b) for subcutaneous injection became the first US FDA-approved immunomodulatory treatment for multiple sclerosis, a chronic inflammatory disease of the CNS. In this review of IFN-beta(1b), we first present a short introduction to multiple sclerosis and currently available therapeutics. ...

journal_title：Expert review of neurotherapeutics

authors： Buttmann M,Rieckmann P

更新日期：2007-03-01 00:00:00

abstract：:Anaplastic astrocytomas (AA), WHO grade III gliomas, comprise 10-15% of all glial neoplasms. Currently, the only factors that have been shown to influence prognosis in patients with AA are age and Karnofsky performance status. Attempts have been made to identify biological prognostic factors for response to therapy an...

journal_title：Expert review of neurotherapeutics

authors： Chamberlain MC,Chowdhary SA,Glantz MJ

更新日期：2008-04-01 00:00:00

abstract：:Introduction: Cognitive impairment and behavioral disturbances are common findings in Parkinson's disease (PD). Despite initially being considered late complications of the disease, it is currently accepted that almost all PD patients will exhibit cognitive and behavioral abnormalities from the early and even the prem...

journal_title：Expert review of neurotherapeutics

authors： Martinez-Horta S,Horta-Barba A,Kulisevsky J

更新日期：2019-07-01 00:00:00

abstract：:Central nervous system idiopathic inflammatory demyelinating disorders are a heterogenous group of diseases that share inflammation and demyelination as key features. Although the exact pathophysiology remains to be fully unveiled, these conditions are challenging to clinicians who seek specific therapeutic options fo...

journal_title：Expert review of neurotherapeutics

authors： Khoshnam M,Freedman MS

更新日期：2012-09-01 00:00:00

abstract：:In different study populations, several studies have shown that modest C-reactive protein elevation, in the range of apparently healthy individuals, is a strong predictor of future vascular events. Willcox and colleagues summarize the epidemiological and clinical observations that have led to the enthusiastic suggesti...

journal_title：Expert review of neurotherapeutics

authors： Di Napoli M,Papa F

更新日期：2004-07-01 00:00:00

abstract：:Constituents of the Cannabis plant, cannabinoids, may be of therapeutic value in neurologic diseases. The most abundant cannabinoids are Δ(9)-tetrahydrocannabinol, which possesses psychoactive properties, and cannabidiol, which has no intrinsic psychoactive effects, but exhibits neuroprotective properties in preclinic...

journal_title：Expert review of neurotherapeutics

authors： Benbadis SR,Sanchez-Ramos J,Bozorg A,Giarratano M,Kalidas K,Katzin L,Robertson D,Vu T,Smith A,Zesiewicz T

更新日期：2014-12-01 00:00:00

abstract：:With improved control of the immunological phenomena of systemic lupus erythematosus, the epidemiology of this disease is changing. While both cardiac and neurological manifestations of systemic lupus erythematosus have been consistently described, there is increasing awareness of the need for general cardiovascular p...

journal_title：Expert review of neurotherapeutics

authors： Wierzbicki AS

更新日期：2002-05-01 00:00:00

abstract：INTRODUCTION:Gait and balance impairments are common in many neurological disorders and among the elderly, are often difficult to treat, and have a significant effect on quality of life. Areas covered: Non-invasive brain stimulation (NIBS) technologies have been recognized for their therapeutic potential in various neu...

journal_title：Expert review of neurotherapeutics

authors： Ghosh S

更新日期：2019-02-01 00:00:00

abstract：:Management issues for patients with brain tumors include peritumoral edema, symptomatic seizures, venous thromboembolism, headache, pain, fatigue and neuropsychological complaints. Vasogenic edema is typically ameliorated with the lowest dose possible of corticosteroid. Seizures are managed with attention to additiona...

journal_title：Expert review of neurotherapeutics

authors： Daly FN,Schiff D

更新日期：2007-10-01 00:00:00

abstract：:Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder of a complex nature. Genetic and environmental factors are thought to be involved in precipitating the disorder. Pharmacological, animal model and recent molecular studies support the role of genes (of minor or medium effect) from dopamine...

journal_title：Expert review of neurotherapeutics

authors： Hawi Z,Kirley A,Lowe N,Fitzgerald M,Gill M

更新日期：2003-07-01 00:00:00

abstract：:Advances in neuroscience have led to an expanded and improved understanding of neurobiological changes associated with rehabilitation and exercise in Parkinson's disease (PD). This knowledge has led to a direct clinical impact of increased referral for early and continuous exercise programs for individuals with PD (ph...

journal_title：Expert review of neurotherapeutics

authors： Sapir S,Ramig LO,Fox CM

更新日期：2011-06-01 00:00:00

abstract：:Cognitive behavioral therapy has been found to be efficacious in the treatment of generalized anxiety disorder (GAD). However, reviews of the clinical significance has indicated that approximately 50% of patients with GAD return to a 'well' status following treatment. So how might the field advance? One way is to base...

journal_title：Expert review of neurotherapeutics

authors： Heiden Cv

更新日期：2013-02-01 00:00:00

abstract：INTRODUCTION:Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron degeneration in the brain and spinal cord. Treatment development for ALS is complicated by complex underlying disease factors. Areas covered: Numerous tested drug compounds have shown no benefits in ALS p...

journal_title：Expert review of neurotherapeutics

authors： Garbuzova-Davis S,Thomson A,Kurien C,Shytle RD,Sanberg PR

更新日期：2016-12-01 00:00:00

abstract：:Introduction: Brivaracetam (BRV) is an analog of levetiracetam (LEV) with 15-30 times greater affinity to SV2A and greater brain permeability than LEV. These properties have stimulated interest in its clinical trial data and post-marketing experience. Areas covered: The authors provide a background on epilepsy and its...

journal_title：Expert review of neurotherapeutics

authors： Makke Y,Abou-Khalil B

更新日期：2019-10-01 00:00:00

abstract：INTRODUCTION:Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer's disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to show statistically significant results supporting their clinica...

journal_title：Expert review of neurotherapeutics

authors： Amanatkar HR,Papagiannopoulos B,Grossberg GT

更新日期：2017-01-01 00:00:00

abstract：:Introduction: Paroxysmal dyskinesias and episodic ataxias are often caused by mutations in genes related to cell membrane and synaptic function. Despite the exponential increase in publications of genetically confirmed cases, management remains largely clinical based on non-systematic evidence. Areas covered: The auth...

journal_title：Expert review of neurotherapeutics

authors： De Gusmao CM,Silveira-Moriyama L

更新日期：2019-09-01 00:00:00

abstract：:The need for maintenance therapy in patients with major depressive disorder (MDD) is underscored by the high likelihood of recurrence after short-term treatment. Current recommendations include treatment to remission and long-term treatment to prevent relapse and recurrence. This article will summarize the design and ...

journal_title：Expert review of neurotherapeutics

authors： Kornstein SG

更新日期：2008-05-01 00:00:00

abstract：:Schizophrenia is a debilitating and pervasive mental illness with devastating effects on psychological, cognitive and social wellbeing, and for which current treatment options are far from ideal. Gender differences and the influence of the female reproductive life cycle on the onset, course and symptoms of schizophren...

journal_title：Expert review of neurotherapeutics

authors： Kulkarni J,Gavrilidis E,Hayes E,Heaton V,Worsley R

更新日期：2012-07-01 00:00:00

abstract：:Advances in molecular biology and virology in recent years have enabled the technology of gene transfer to proceed forward. Parkinson's disease (PD) is a particularly appropriate target for gene therapy since the brain pathology is fully characterized and relatively well circumscribed largely within the nigrostriatal ...

journal_title：Expert review of neurotherapeutics

authors： Mochizuki H

更新日期：2007-08-01 00:00:00

abstract：:Cognitive-behavioral therapy (CBT) originated as a treatment for emotional disorders. However, it is increasingly used to help people with chronic illnesses manage symptoms and improve psychosocial outcomes, such as depression and quality of life. In this article, we focus on uses of CBT in patients with multiple scle...

journal_title：Expert review of neurotherapeutics

authors： Dennison L,Moss-Morris R

更新日期：2010-09-01 00:00:00

abstract：:Guanfacine is an α2A-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and...

journal_title：Expert review of neurotherapeutics

authors： Rizzo R,Martino D

更新日期：2015-04-01 00:00:00

abstract：:Over the last decade, much progress has been made towards identifying risk factors for schizophrenia. It is now thought that many genes of small effect contribute towards risk of developing schizophrenia and some of these probably confer susceptibility to environmental factors. Large population-based studies, using re...

journal_title：Expert review of neurotherapeutics

authors： Boydell J

更新日期：2001-11-01 00:00:00

abstract：:Sumatriptan 85 mg with naproxen sodium 500 mg, a combination tablet for the acute treatment of migraine, is approved in the USA. It is likely that triptan/NSAID combination benefits are a class effect, although the majority of data are on sumatriptan and naproxen sodium. The combination tablet demonstrated superior ef...

journal_title：Expert review of neurotherapeutics

authors： Cleves C,Tepper SJ

更新日期：2008-09-01 00:00:00

abstract：:An influence of climate upon cerebrovascular risk is both biologically plausible and supported by epidemiological evidence. These relationships are important as they could yield public health strategies to help protect the vulnerable from the increased death rates arising during extreme cold and heat waves. Change in ...

journal_title：Expert review of neurotherapeutics

authors： McArthur K,Dawson J,Walters M

更新日期：2010-02-01 00:00:00

abstract：:Alzheimer's disease is common, incurable and disabling. It is expected to grow dramatically in prevalence over the next 50 years. At current, the standard of care for patients with mild and moderately severe Alzheimer's disease includes the use of acetylcholinesterase inhibitors. Donepezil (Aricept) is a highly select...

journal_title：Expert review of neurotherapeutics

authors： Geldmacher DS

更新日期：2004-01-01 00:00:00

abstract：:Advances in research and better understanding of the pathophysiology of diseases have resulted in an increase in the number of available health interventions that compete for finite public resources. Explicit choices must therefore be made about funding. ...

journal_title：Expert review of neurotherapeutics

authors： Kobelt G

更新日期：2013-12-01 00:00:00

abstract：:The American Academy of Neurology is an international professional organization of more than 22,000 neurologists and neuroscience professionals. This year the annual meeting was held in Toronto, ON, Canada. A large number of scientific sessions presented numerous advances in the diagnosis, molecular pathogenesis and t...

journal_title：Expert review of neurotherapeutics

authors： Yiu EM,Banwell B

更新日期：2010-08-01 00:00:00

abstract：:Gliomas constitute the most frequent and malignant primary brain tumors. Current standard therapeutic strategies (surgery, radiotherapy and chemotherapeutics, e.g., temozolomide, carmustin or carboplatin) for their treatment are only palliative and survival diagnosis is normally 6-12 months. The development of new the...

journal_title：Expert review of neurotherapeutics

authors： Parolaro D,Massi P

更新日期：2008-01-01 00:00:00

abstract：INTRODUCTION:Calcitonin Gene-Related Peptide (CGRP) has gradually emerged as a suitable therapeutic target to treat migraine. Considering the social and economic burden of migraine, it is fundamental to optimize the disease management with efficacious and safe treatments. In this scenario, drugs targeting GCRP, monoclo...

journal_title：Expert review of neurotherapeutics

authors： De Matteis E,Guglielmetti M,Ornello R,Spuntarelli V,Martelletti P,Sacco S

更新日期：2020-06-01 00:00:00

abstract：:Non-pharmacological interventions have the potential to reduce cognitive decline and to improve psychosocial aspects in mild cognitive impairment and Alzheimer's dementia, and the absence of side effects makes them a favorable option also for preventive strategies. We provide an overview on recent studies involving co...

journal_title：Expert review of neurotherapeutics

authors： Herholz SC,Herholz RS,Herholz K

更新日期：2013-11-01 00:00:00